Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 8, Issue 3, Pages 344
Publisher
MDPI AG
Online
2019-03-13
DOI
10.3390/jcm8030344
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
- (2019) Tomas Kalincik et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study
- (2019) Robert Zivadinov et al. Journal of Comparative Effectiveness Research
- Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis
- (2018) R. Zivadinov et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures
- (2018) Robert Zivadinov et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Estimates of age-dependent cutoffs for pathological brain volume loss using SIENA/FSL—a longitudinal brain volumetry study in healthy adults
- (2018) Roland Opfer et al. NEUROBIOLOGY OF AGING
- Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis
- (2018) Laura Gaetano et al. NEUROLOGY
- Teriflunomide's Effect on Glia in Experimental Demyelinating Disease: A Neuroimaging and Histologic Study
- (2018) Suyog Pol et al. JOURNAL OF NEUROIMAGING
- Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study
- (2018) S. Condé et al. EUROPEAN JOURNAL OF NEUROLOGY
- Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry
- (2018) Stefan Braune et al. JOURNAL OF NEUROLOGY
- Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience
- (2018) E. D’Amico et al. JOURNAL OF NEUROLOGY
- Leptomeningeal Enhancement at 7T in Multiple Sclerosis: Frequency, Morphology, and Relationship to Cortical Volume
- (2017) Daniel M. Harrison et al. JOURNAL OF NEUROIMAGING
- Global and regional annual brain volume loss rates in physiological aging
- (2017) Sven Schippling et al. JOURNAL OF NEUROLOGY
- A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis
- (2017) Fawad Yousuf et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Effect of teriflunomide on cortex-basal ganglia-thalamus (CxBGTh) circuit glutamatergic dysregulation in the Theiler's Murine Encephalomyelitis Virus mouse model of multiple sclerosis
- (2017) Claire M. Modica et al. PLoS One
- Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication
- (2017) Andrea Bilger et al. Oncotarget
- Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
- (2017) Ann Marie Weideman et al. Frontiers in Neurology
- Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine
- (2016) Robert Zivadinov et al. Expert Review of Neurotherapeutics
- Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study
- (2016) Omar Khan et al. Multiple Sclerosis Journal
- Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study
- (2016) Robert Zivadinov et al. Multiple Sclerosis Journal
- A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients
- (2016) Robert Zivadinov et al. Multiple Sclerosis Journal
- Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine
- (2016) Robert Zivadinov et al. Expert Review of Neurotherapeutics
- Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study
- (2016) Omar Khan et al. Multiple Sclerosis Journal
- Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study
- (2016) Robert Zivadinov et al. Multiple Sclerosis Journal
- A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients
- (2016) Robert Zivadinov et al. Multiple Sclerosis Journal
- Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
- (2015) D. H. Miller et al. NEUROLOGY
- Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis
- (2015) Martina Absinta et al. NEUROLOGY
- Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
- (2014) Amit Bar-Or EXPERIMENTAL NEUROLOGY
- Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study
- (2014) Douglas L. Arnold et al. JOURNAL OF NEUROLOGY
- Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Aaron E Miller et al. LANCET NEUROLOGY
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Brain atrophy in natalizumab-treated patients: A 3-year follow-up
- (2014) J Sastre-Garriga et al. Multiple Sclerosis Journal
- Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years
- (2013) R. Zivadinov et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Dimethyl Fumarate for Treatment of Multiple Sclerosis: Mechanism of Action, Effectiveness, and Side Effects
- (2013) Ralf A. Linker et al. Current Neurology and Neuroscience Reports
- Validation of the automated method VIENA: An accurate, precise, and robust measure of ventricular enlargement
- (2013) Hugo Vrenken et al. HUMAN BRAIN MAPPING
- Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
- (2013) M. Filippi et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes
- (2013) Angela Vidal-Jordana et al. Multiple Sclerosis Journal
- Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model
- (2013) Michael G. Dwyer et al. NEUROIMAGE
- Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study
- (2012) E. Portaccio et al. EUROPEAN JOURNAL OF NEUROLOGY
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
- (2011) Chris H. Polman et al. ANNALS OF NEUROLOGY
- The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis
- (2011) Rose Gelineau-Morel et al. HUMAN BRAIN MAPPING
- 3D FLAIRED: 3D fluid attenuated inversion recovery for enhanced detection of lesions in multiple sclerosis
- (2011) Paul Polak et al. MAGNETIC RESONANCE IN MEDICINE
- A Bayesian model of shape and appearance for subcortical brain segmentation
- (2011) Brian Patenaude et al. NEUROIMAGE
- The predictive value of gray matter atrophy in clinically isolated syndromes
- (2011) M. Calabrese et al. NEUROLOGY
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gray matter atrophy in multiple sclerosis: A longitudinal study
- (2008) Elizabeth Fisher et al. ANNALS OF NEUROLOGY
- Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
- (2008) R. Zivadinov et al. NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More